Phase 3 N=63 Randomized Treatment

Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?

Glaucoma

Bottom Line

View on ClinicalTrials.gov: NCT00853073 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2015

Primary outcome: Primary: Intraocular Pressure (IOP) — 11.52; 12.83 mmHg (millimeters of mercury)

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: bevacizumab (Drug); balanced salt solution (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Wills Eye
Primary completion: Jan 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Intraocular Pressure (IOP)	11.52; 12.83	—
SECONDARY Number of Participants With Surgical Success	17; 12; 0; 2; 12; 15	—

Summary

The purpose of this study is to see if a new add on (or adjunctive) therapy used in glaucoma surgery improves the success of needle bleb revisions.

Eligibility Criteria

Inclusion Criteria

require glaucoma bleb needle revision with Mitomycin-C

Exclusion Criteria

pregnant, nursing, or not using adequate contraception
other glaucoma eye surgery involving tube shunts
prior retinal detachments surgery with scleral buckle
infection, inflammation, or any abnormality preventing eye pressure measurement
enrolled in another investigational study

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00853073). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.